Showing 51-60 of 7551 results for "".
Coding and Reimbursement Tips for 2022
https://practicaldermatology.com/topics/practice-management/coding-and-reimbursement-tips-for-2022/20045/After mitigating a proposed 10 percent cut in Medicare payments to a two percent cut, Mark Kaufmann, MD stresses the importance of dermatologists advocating for raising reimbursement rates. He also discusses best practices for billing and coding.Keeping Tech in Check
https://practicaldermatology.com/topics/practice-management/keeping-tech-in-check/18427/Dermatologist and their patients can benefit from advances in technology, but the key is that new tools and data are used properly. Neal Bhatia, MD asks Mark Kaufmann, MD how dermatologists can advocate for their specialty and what initiatives are underway.DermWireTV: NPF on Boosters; Galderma Raises Awareness, World Eczema Day, and more
https://practicaldermatology.com/topics/psoriasis/dermwiretv-npf-on-boosters-galderma-raises-awareness-world-eczema-day-and-more/20002/Launched on World Eczema Day, the Global Patient Initiative to Improve Eczema Care represents 11 patient organizations from eight countries. The initiative is supported with funding from LEO Pharma. GlobalSkin marked World Eczema Day by calling on health care professionals, health policy decision maThe Landscape of Vitiligo Treatment
https://practicaldermatology.com/series/updates-vitiligo/the-landscape-of-vitiligo-treatment/24467/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, talks with Lawrence Green, MD, a dermatologist practicing in Rockville, MD, about the landscape of treatments for patients with vitiligo and new therapies that may be coming from ongoing clinical trials.DermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global PCoding Challenges
https://practicaldermatology.com/topics/practice-management/coding-challenges/19741/Mark Kaufmann, MD discusses changing coding issues that will affect most dermatologists, including the need to get educated about new evaluation and management codes for 2021, modifier 25 issues, and global period codes being under pressure.DermWireTV: Impact of COVID-19 on Dermatology
https://practicaldermatology.com/topics/practice-management/dermwiretv-impact-of-covid-19-on-dermatology/19878/As COVID-19 infections surge across the US, a vaccine has been approved. What's it mean for dermatology patients? And how is the pandemic impacting dermatology practices? Updates from the International Psoriasis Council; Mark Nestor, MD; Amy Taub, MD; Terrence Keaney, MD; and Melissa Kanchanapoomi LStrategies for Success: Tips on Running a Successful Dermatology Practice
https://practicaldermatology.com/conferences/scale-2023/strategies-for-success-tips-on-running-a-successful-dermatology-practice/20199/Mark D. Kaufmann, MD, Chief Medical Officer of Advanced Dermatology and Cosmetic Surgery Clinics, discusses what it takes to run a successful dermatology practice today, including the importance of leveraging data to prove value and sharpening business skills.Improving the After-Sun Treatment Market
https://practicaldermatology.com/series/c-suite-chats/improving-after-sun-treatment-market/29805/Ed Esquenazi, PhD, Founder and CEO of health and performance company, Terns, discusses the after-sun treatment market and two new products designed to combat inflammation and aging after exposure to the sun.The Dermatology and Aesthetics Market: Continued Mergers and Acquisitions Momentum and Emerging Trends
https://practicaldermatology.com/topics/practice-management/the-dermatology-and-aesthetics-market-continued-mergers-and-acquisitions-momentum-and-emerging-trends/23679/The resilience of the dermatology and aesthetics market, coupled with growth opportunities, continues to fuel the M&A trend.